Ocular Therapeutix Inc (NASDAQ:OCUL) has a beta value of 1.29 and has seen 2.3 million shares traded in the last trading session. The company, currently valued at $1.60B, closed the last trade at $10.23 per share which meant it lost -$0.23 on the day or -2.20% during that session. The OCUL stock price is -10.56% off its 52-week high price of $11.31 and 80.45% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.69 million shares traded. The 3-month trading volume is 1.21 million shares.

The consensus among analysts is that Ocular Therapeutix Inc (OCUL) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.24.

Ocular Therapeutix Inc (NASDAQ:OCUL) trade information

Sporting -2.20% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the OCUL stock price touched $10.23 or saw a rise of 4.03%. Year-to-date, Ocular Therapeutix Inc shares have moved 129.37%, while the 5-day performance has seen it change 9.76%. Over the past 30 days, the shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have changed 14.56%. Short interest in the company has seen 16.19 million shares shorted with days to cover at 14.29.

Wall Street analysts have a consensus price target for the stock at $16, which means that the shares’ value could jump 36.06% from current levels. The projected low price target is $14.0 while the price target rests at a high of $24.0. In that case, then, we find that the current price level is -134.6% off the targeted high while a plunge would see the stock gain -36.85% from current levels.

Ocular Therapeutix Inc (OCUL) estimates and forecasts

Figures show that Ocular Therapeutix Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 31.32% over the past 6 months, with this year growth rate of -13.73%, compared to 17.60% for the industry. Revenue growth from the last financial year stood is estimated to be 13.20%.

8 analysts offering their estimates for the company have set an average revenue estimate of 17.13M for the current quarter. 8 have an estimated revenue figure of 17.75M for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 8.38% over the past 5 years.

OCUL Dividends

Ocular Therapeutix Inc is expected to release its next earnings report in November this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Ocular Therapeutix Inc (NASDAQ:OCUL)’s Major holders

Insiders own 1.19% of the company shares, while shares held by institutions stand at 89.30% with a share float percentage of 90.37%. Investors are also buoyed by the number of investors in a company, with Ocular Therapeutix Inc having a total of 208.0 institutions that hold shares in the company. The top two institutional holders are SUMMER ROAD LLC with over 14.89 million shares worth more than $101.82 million. As of 2024-06-30, SUMMER ROAD LLC held 11.2751% of shares outstanding.

The other major institutional holder is VR ADVISER, LLC, with the holding of over 12.76 million shares as of 2024-06-30. The firm’s total holdings are worth over $87.3 million and represent 9.6669% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 2.90% shares in the company for having 4.52 shares of worth $46.21 million while later fund manager owns 4.18 shares of worth $42.72 million as of Aug 31, 2024 , which makes it owner of about 2.68% of company’s outstanding stock.